As of November 6, 2026, 4 holders' latest Schedule 13D or 13G filings report owning 5% or more of OKYO Pharma Ltd. The largest reported stake is Chernett Jorey's, at 9.5%. 10 filings are on record since August 5, 2025 (Schedule 13G/A, February 13, 2026).
Sell to companies like OKYO Pharma Ltd? Enter your website and see 10 with a filed reason to buy from you this month. Free.
Opens in a new tab. No signup.
Key facts
- · Reporting person: Sirenia Capital Management LP · Sole voting: 0 · Shared voting: 4,054,054 · Sole dispositive: 0 · Shared dispositive: 4,054,054 · SCHEDULE 13G, 2026-05-15
- · Reporting person: Woodline Partners LP · Sole voting: 3,652,190 · Shared voting: 0 · Sole dispositive: 3,652,190 · Shared dispositive: 0 · SCHEDULE 13G, 2026-05-15
- · Reporting person: Point72 Asset Management, L.P. · Sole voting: 0 · Shared voting: 0 · Sole dispositive: 0 · Shared dispositive: 0 · SCHEDULE 13G/A, 2026-05-15
- · Holder: Point72 Asset Management, L.P. · Percent: 7.9% · SCHEDULE 13G
- · Holder: Chernett Jorey · Percent: 9.5% · SCHEDULE 13G/A
OKYO Pharma Ltd has 10 Schedule 13D or 13G filings on record since 2025-08-05. 4 holders' latest filing reports 5% or more of ordinary shares, no par value. Each figure below is the holder's own, as filed, with the filing linked.
Holders
| Holder | Percent | Shares | Latest | Event date |
|---|---|---|---|---|
| 9.5% | 3,802,194 | SCHEDULE 13G/A, 2026-02-13 | 2025-12-31 | |
| Sirenia Capital Management LP | 7.7% | 4,054,054 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| Woodline Partners LP | 7% | 3,652,190 | SCHEDULE 13G, 2026-05-15 | 2026-03-31 |
| 5.01% | 1,928,451 | SCHEDULE 13G, 2025-10-29 | 2025-07-22 | |
| Dauntless Investment Group, LLC | 1.2% | 471,523 | SCHEDULE 13G/A, 2026-02-12 | 2025-12-31 |
| Point72 Asset Management, L.P. | 0% | 0 | SCHEDULE 13G/A, 2026-05-15 | 2026-03-31 |
Holding shares or following this stake? See who's behind OKYO Pharma Ltd and the warning signs.
Free to see. No signup.
Keep reading
More on OKYO Pharma Ltd and the records around it.
OKYO Pharma Ltd elsewhere on the record
Companies that share a holder
- Dauntless Investment Group, LLC also filed stake reports on 3 other companies: KAZIA THERAPEUTICS LTD (Oct 2026), Azitra, Inc. (Jun 2026), FEMASYS INC (Nov 2025)
- Chernett Jorey also filed stake reports on 16 other companies: CVRx, Inc. (Oct 2026), WW INTERNATIONAL, INC. (Aug 2026), Neuronetics, Inc. (Aug 2026)
- Sirenia Capital Management LP also filed stake reports on 19 other companies: Alto Neuroscience, Inc. (Aug 2026), ANAPTYSBIO, INC (Aug 2026), CYBIN INC. (Aug 2026)
Watch OKYO Pharma Ltd
Get an email when OKYO Pharma Ltd files again: a new raise, a leadership change, a layoff or an IPO filing. One email first to confirm; nothing else until you click it. At most one a day, one click to stop. Free for up to 3 companies.
Want the whole picture on OKYO Pharma Ltd?
Example from a real report (our sample on Target): “In March 2026, Target announced a planned incremental $1 billion operating investment” Source: Target Corporation (press release)
A Full Report on OKYO Pharma Ltd: verified, sourced, every claim cited, ready in a few minutes. See pricing.
What the Full Report on OKYO Pharma Ltd covers
The Short Answer
Which Company This Is
What They Do, And How The Money Works
Who Runs It, And How To Reach Them
The Money: Funding, Valuation, Runway
Who Pays Them, And Who They Are Up Against
Warning Bells
Sources
10 cited sources found
Plus the sections for what you are deciding, which you pick after ordering.
A real finished report, first screen. Opens in a new tab.
Not ready to order yet? Keep this snapshot.
Sends this preview to you once; we won't add you to any list
Voting and dispositive power, as filed
| Reporting person | Sole voting | Shared voting | Sole dispositive | Shared dispositive | Filing |
|---|---|---|---|---|---|
| Sirenia Capital Management LP | 0 | 4,054,054 | 0 | 4,054,054 | SCHEDULE 13G, 2026-05-15 |
| Alex Silverstein | 0 | 4,054,054 | 0 | 4,054,054 | SCHEDULE 13G, 2026-05-15 |
| Woodline Partners LP | 3,652,190 | 0 | 3,652,190 | 0 | SCHEDULE 13G, 2026-05-15 |
| Point72 Asset Management, L.P. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Point72 Capital Advisors, Inc. | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
| Steven A. Cohen | 0 | 0 | 0 | 0 | SCHEDULE 13G/A, 2026-05-15 |
The latest filing identifies OKYO Pharma Ltd by CUSIP G6724L116 and gives its principal executive office as 55 PARK LANE, LONDON (SCHEDULE 13G, 2026-05-15).
Timeline
| Filed | Holder | Percent | Filing |
|---|---|---|---|
| 2025-08-05 | Dauntless Investment Group, LLC | 7.3% | SCHEDULE 13G/A |
| 2025-10-29 | Laura Natalia Monica Fonda | 5.01% | SCHEDULE 13G |
| 2025-11-14 | Chernett Jorey | 7.8% | SCHEDULE 13G/A |
| 2025-11-14 | Dauntless Investment Group, LLC | 6.3% | SCHEDULE 13G/A |
| 2026-02-12 | Dauntless Investment Group, LLC | 1.2% | SCHEDULE 13G/A |
| 2026-02-13 | Chernett Jorey | 9.5% | SCHEDULE 13G/A |
| 2026-02-18 | Point72 Asset Management, L.P. | 7.9% | SCHEDULE 13G |
| 2026-05-15 | Sirenia Capital Management LP | 7.7% | SCHEDULE 13G |
| 2026-05-15 | Woodline Partners LP | 7% | SCHEDULE 13G |
| 2026-05-15 | Point72 Asset Management, L.P. | 0% | SCHEDULE 13G/A |
Questions about who owns OKYO Pharma Ltd
Who owns OKYO Pharma Ltd?
On this page, 4 holders' latest ownership filings report 5% or more of OKYO Pharma Ltd: Chernett Jorey (9.5%, Schedule 13G/A, filed 2026-02-13), Sirenia Capital Management LP (7.7%, Schedule 13G, filed 2026-05-15), Woodline Partners LP (7%, Schedule 13G, filed 2026-05-15) and Laura Natalia Monica Fonda (5.01%, Schedule 13G, filed 2025-10-29).
Who are the largest shareholders of OKYO Pharma Ltd?
By the share each holder's latest filing reports, the largest holders of OKYO Pharma Ltd on this page are Chernett Jorey (9.5%), Sirenia Capital Management LP (7.7%) and Woodline Partners LP (7%).
When did Chernett Jorey buy into OKYO Pharma Ltd?
The filings give report dates, not purchase dates. The earliest filing from Chernett Jorey on this page is the Schedule 13G/A, filed 2025-11-14, reporting 7.8%; its latest, Schedule 13G/A filed 2026-02-13, reports 9.5%. That earliest filing is itself an amendment, which updates an earlier report.
Is this an audit or a full list?
Neither. The ownership list on this page covers only Schedule 13D and 13G filings, which holders make once they own 5% or more of a class of shares (an amendment can report a stake that has since fallen below 5%); 10 such filings are shown here. It is not an audit and not a full cap table: holders who never reached 5% are not listed, and a stake can change after its latest filing.
Tools for this story
Each opens in a new tab, filled in for OKYO Pharma Ltd. With no account yet, you sign up free and land on the result.
Where this comes from
Anyone who comes to own more than 5% of a class of a listed company's voting shares has to tell the SEC. A holder who may seek to change or influence the company files Schedule 13D, and has to say in Item 4, "Purpose of Transaction", what it intends to do. A holder with no such intent, such as many index and passive funds, may file the shorter Schedule 13G. Both are amended when the stake changes, including when it falls below 5%.
Every row here is one of those filings, linked to the filing itself. Percentages and share counts are exactly as the holder filed them, for the holder the filing names; an amendment showing a lower figure is shown as filed. Item 4 text is quoted word for word. Where a 13D's Item 4 contains a sentence stating a definite intent to influence the company, that sentence is marked and quoted; the page does not describe the holder or its motives beyond the words it filed. Nothing here is investment advice.